1. Home
  2. STKL vs LCTX Comparison

STKL vs LCTX Comparison

Compare STKL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SunOpta Inc.

STKL

SunOpta Inc.

HOLD

Current Price

$6.44

Market Cap

454.0M

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.68

Market Cap

366.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKL
LCTX
Founded
1973
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
454.0M
366.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
STKL
LCTX
Price
$6.44
$1.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$7.83
$4.67
AVG Volume (30 Days)
4.4M
1.2M
Earning Date
02-26-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$792,436,000.00
$10,816,000.00
Revenue This Year
$13.49
$6.32
Revenue Next Year
$7.13
$124.49
P/E Ratio
$150.14
N/A
Revenue Growth
11.95
24.05
52 Week Low
$3.32
$0.37
52 Week High
$7.68
$2.09

Technical Indicators

Market Signals
Indicator
STKL
LCTX
Relative Strength Index (RSI) 84.43 48.50
Support Level $4.78 $1.65
Resistance Level $6.44 $1.90
Average True Range (ATR) 0.11 0.12
MACD 0.15 0.01
Stochastic Oscillator 99.49 46.67

Price Performance

Historical Comparison
STKL
LCTX

About STKL SunOpta Inc.

SunOpta Inc is a Canadian company that focuses on a healthy product portfolio. The company is a manufacturer for natural and private label brands and also produces its own propriety brands, including SOWN, Dream and West Life. The core of its product portfolio is a range of plant-based beverages, including oat, almond, soy, coconut and rice milks and creamers, which have a favorable climate profile relative to traditional dairy milks in terms of lower carbon emissions and water usage. Their plant-based offerings include non-genetically modified, organic, and gluten-free products. The consumer products portfolio also includes protein shakes, teas, broths, and fruit snacks. Geographically, the company operates in U.S, Canada and Others, out of which it derives maximum revenue from U.S.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: